Open AccessSomatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients
Author(s) -
Po Yang,
Milind Javle,
Fei Pang,
Wei Zhao,
Reham Abdel-Wahab,
Xiaofeng Chen,
Funda MericBernstam,
Huanwei Chen,
Mitesh J. Borad,
Yu Liu,
Chuntao Zou,
Shuo Mu,
Yanfeng Xing,
Kai Wang,
Chuang Peng,
Xu Che
Publication year - 2019
Publication title -
hepatobiliary surgery and nutrition
Language(s) - English
Resource type - Journals
eISSN - 2304-389X
pISSN - 2304-3881
DOI - 10.21037/hbsn.2019.04.11
Subject(s) - cdkn2a , medicine , gemcitabine , cohort , oncology , gallbladder cancer , cancer , arid1a , mutation , gene , genetics , biology
Gallbladder cancer (GBC) is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. The five-year survival rate of this cancer when diagnosed at an advanced stage is below 5%, and the median survival time is less than a year with standard gemcitabine-based chemotherapy. Survival benefit with second-line treatment is unknown. Thus, there is an urgent need for novel treatment strategies and targeted therapy based on next generation sequencing (NGS) may be of value.